HC Wainwright Forecasts Strong Price Appreciation for TG Therapeutics (NASDAQ:TGTX) Stock

TG Therapeutics (NASDAQ:TGTX) had its price target upped by HC Wainwright from $49.00 to $55.00 in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

TGTX has been the topic of a number of other research reports. B. Riley raised their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday. Finally, TD Cowen initiated coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target for the company. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

TG Therapeutics Trading Up 6.2 %

TGTX opened at $25.86 on Tuesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58. TG Therapeutics has a one year low of $9.81 and a one year high of $26.99. The company has a market cap of $4.00 billion, a P/E ratio of -258.00 and a beta of 2.19. The business’s 50-day simple moving average is $23.51 and its 200-day simple moving average is $20.17.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The company had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. During the same quarter in the prior year, the company earned $0.73 earnings per share. The business’s revenue for the quarter was down 49.4% on a year-over-year basis. As a group, equities research analysts expect that TG Therapeutics will post 0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On TG Therapeutics

Institutional investors have recently bought and sold shares of the company. Swiss National Bank boosted its holdings in shares of TG Therapeutics by 0.5% in the first quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock valued at $4,321,000 after acquiring an additional 1,500 shares in the last quarter. Quantum Private Wealth LLC boosted its holdings in TG Therapeutics by 13.7% in the 1st quarter. Quantum Private Wealth LLC now owns 103,604 shares of the biopharmaceutical company’s stock valued at $1,576,000 after purchasing an additional 12,523 shares in the last quarter. Sei Investments Co. acquired a new position in TG Therapeutics during the 1st quarter worth approximately $591,000. Russell Investments Group Ltd. raised its stake in shares of TG Therapeutics by 133.5% during the 1st quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company’s stock worth $796,000 after buying an additional 29,923 shares in the last quarter. Finally, ProShare Advisors LLC lifted its holdings in shares of TG Therapeutics by 8.5% in the 1st quarter. ProShare Advisors LLC now owns 24,914 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 1,961 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.